<em>Mergers & Acquisitions</em> and Law360 report Fried Frank's representation of Lazard in connection with Cornerstone Therapeutics'  US$255 million going-private transaction

Mergers & Acquisitions and Law360 report Fried Frank's representation of Lazard in connection with Cornerstone Therapeutics'  US$255 million going-private transaction

Mergers & Acquisitions and Law360 reported the Firm's representation of Lazard, financial advisor to the Special Committee of Cornerstone Therapeutics, in connection with a US$255 million going-private transaction in which Chiesi Farmaceutici is acquiring the 42 percent of Cornerstone's shares it does not already own.

news-detail.inc